MX2017012113A - Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. - Google Patents

Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.

Info

Publication number
MX2017012113A
MX2017012113A MX2017012113A MX2017012113A MX2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A
Authority
MX
Mexico
Prior art keywords
combination
deacetilase
histona
inhibitor
cancer treatment
Prior art date
Application number
MX2017012113A
Other languages
English (en)
Spanish (es)
Inventor
Goodenow Robert
Ordentlich Peter
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56977796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017012113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of MX2017012113A publication Critical patent/MX2017012113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2017012113A 2015-03-20 2016-03-18 Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. MX2017012113A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136303P 2015-03-20 2015-03-20
US201562137601P 2015-03-24 2015-03-24
PCT/US2016/023298 WO2016154068A1 (en) 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2017012113A true MX2017012113A (es) 2018-07-06

Family

ID=56977796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012113A MX2017012113A (es) 2015-03-20 2016-03-18 Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.

Country Status (11)

Country Link
US (3) US11324822B2 (https=)
EP (1) EP3270966B1 (https=)
JP (3) JP2018508593A (https=)
KR (1) KR20170124604A (https=)
CN (1) CN107614011A (https=)
AU (2) AU2016235434B2 (https=)
BR (1) BR112017020002A2 (https=)
ES (1) ES2986548T3 (https=)
IL (3) IL254529B2 (https=)
MX (1) MX2017012113A (https=)
WO (1) WO2016154068A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016318136B2 (en) 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
US20190183870A1 (en) * 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
RU2018130831A (ru) 2016-01-28 2020-03-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11497746B2 (en) 2016-11-23 2022-11-15 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
KR20200051712A (ko) * 2017-09-08 2020-05-13 4에스체 악티엔게젤샤프트 암 치료를 위한 면역 체크포인트 조절제와 조합된 hdac 억제제
US20210024633A1 (en) * 2018-03-28 2021-01-28 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
AU2019266231B2 (en) * 2018-05-07 2025-08-21 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
AU2019285640A1 (en) 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
WO2019240872A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
WO2021129616A1 (zh) * 2019-12-23 2021-07-01 信达生物制药(苏州)有限公司 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
WO2024222705A1 (zh) * 2023-04-25 2024-10-31 深圳微芯生物科技股份有限公司 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途
US20240382463A1 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition Comprising HDAC Inhibitor and Immune Checkpoin Inhibitor and Methods For Using the Same
US12553903B2 (en) 2023-06-01 2026-02-17 Cg Pharmaceuticals, Inc Ivaltinostat combination therapy for treating pancreatic cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US20130150386A1 (en) 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
US8987067B2 (en) * 2013-03-01 2015-03-24 International Business Machines Corporation Segmented guard ring structures with electrically insulated gap structures and design structures thereof
CA2917858A1 (en) * 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
US10869926B2 (en) * 2014-07-15 2020-12-22 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US20180353602A1 (en) * 2015-06-29 2018-12-13 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
AU2016318136B2 (en) * 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy

Also Published As

Publication number Publication date
JP2024091945A (ja) 2024-07-05
KR20170124604A (ko) 2017-11-10
US20180078639A1 (en) 2018-03-22
US20230022573A1 (en) 2023-01-26
NZ735686A (en) 2024-07-26
IL323063A (en) 2025-10-01
AU2022202954A1 (en) 2022-05-26
IL254529B2 (en) 2024-05-01
JP7540980B2 (ja) 2024-08-27
JP2018508593A (ja) 2018-03-29
IL307850A (en) 2023-12-01
AU2016235434B2 (en) 2022-02-03
BR112017020002A2 (en) 2018-06-19
US11324822B2 (en) 2022-05-10
US20240398944A1 (en) 2024-12-05
EP3270966B1 (en) 2024-05-01
HK1250142A1 (en) 2018-11-30
EP3270966A4 (en) 2018-10-17
EP3270966A1 (en) 2018-01-24
AU2016235434A1 (en) 2017-10-12
ES2986548T3 (es) 2024-11-11
CN107614011A (zh) 2018-01-19
JP2021175754A (ja) 2021-11-04
RU2017134315A (ru) 2019-04-03
WO2016154068A1 (en) 2016-09-29
CA2980297A1 (en) 2016-09-29
RU2017134315A3 (https=) 2019-09-12
IL254529B1 (en) 2024-01-01
IL254529A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
MX2017012113A (es) Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
HK1255916A1 (zh) 组织蛋白去乙醯酶抑制剂与免疫检查点抑制抗体的合并癌症治疗
MX2022002959A (es) Anticuerpos anti-tigit y metodos de uso.
MX389204B (es) Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cáncer hematológico.
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
WO2016062722A8 (en) Combination
MX2020000960A (es) Anticuerpos anti-tigit.
EP3733704A4 (en) Anti-pd-l1 antibody and uses thereof
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
PT3142751T (pt) Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células.
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
BR112017004270A2 (pt) complexos de anticorpos solúveis para células t ou ativação e expansão de células nk
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
HK1244681A1 (zh) 用於治疗肿瘤形成的治疗组合和方法
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2018008008A (es) Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE